Illumina and Labcorp expanded their collaboration to advance precision oncology using next-generation sequencing solutions. The companies plan projects to broaden access to cancer biomarker testing through distributed test offerings and to generate evidence to support payer coverage. They will explore co-commercializing Labcorp’s FDA-authorized liquid biopsy assay PGDx elio plasma focus Dx with Illumina’s FDA-approved TruSight Oncology Comprehensive for solid tumor profiling. Illumina and Labcorp also plan to develop new in vitro diagnostic tests for comprehensive genomic profiling and whole-genome sequencing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief on March 18, 2026, and is solely responsible for the information contained therein.